PD-1/PD-L1 Antibodies & Proteins: Research Reagents for Immune Checkpoint Studies

PD-1 (programmed death-1, CD279) and its primary ligand PD-L1 (CD274) form the most clinically validated immune checkpoint axis in oncology.

Target Biology and Clinical Relevance

PD-1 is expressed on activated T cells, B cells, and NK cells. PD-L1 is expressed on tumor cells, antigen-presenting cells, and stromal cells. Binding of PD-L1 to PD-1 delivers an inhibitory signal that suppresses T cell cytokine production, proliferation, and survival — enabling tumor immune evasion.

Six anti-PD-1/PD-L1 antibodies are now approved for cancer treatment: pembrolizumab, nivolumab, cemiplimab (anti-PD-1); atezolizumab, durvalumab, avelumab (anti-PD-L1). Research biosimilar versions of all six are available for laboratory use.

Anti-PD-L1 IHC is widely used as a companion diagnostic to predict response to checkpoint immunotherapy. Research-use PD-L1 antibodies enable expression scoring on FFPE tissue, though staining patterns may differ from the FDA-approved diagnostic clones (22C3, 28-8, SP142, SP263).

Flow cytometry applications include: surface PD-1 staining on T cells for exhaustion profiling, PD-L1 staining on tumor cells for expression analysis, and intracellular PD-1 staining after permeabilization for total PD-1 quantification.

Recombinant PD-1 ECD and PD-L1 ECD proteins are used as coating antigens for ELISA, ligands for SPR/BLI binding kinetics, and blocking reagents in competitive binding assays. His-tagged and Fc-tagged versions are available for different capture strategies.

abinScience Product Coverage

References

1. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567. doi: 10.1038/nature14011

2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi: 10.1038/nrc3239

All products are for research use only. For technical support, contact order@abinscience.com.